alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



     In connection  with the Quarterly  Report of CEC  Entertainment,  Inc. (the
"Company") on Form 10-Q/A for the quarter ended March 28, 2004 as filed with the
Securities  and  Exchange  Commission  on the date  hereof (the  "Report"),  the
undersigned  certifies,  pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:


     (1)  The Report fully  complies with the  requirements  of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.



                                            /s/ Christopher D. Morris
                                            ------------------------------
                                            Christopher D. Morris
                                            Chief Financial Officer
                                            March 18, 2005



A signed  original of this  written  statement  required by Section 906 has been
provided to CEC  Entertainment,  Inc. and will be retained by CEC Entertainment,
Inc. and furnished to the Securities  and Exchange  Commission or its staff upon
request.
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.5680 Automated heparin analyzer. ( a ) *Identification.* An automated heparin analyzer is a device used to determine the heparin level in a blood sample by mixing the sample with protamine (a heparin-neutralizing substance) and determining photometrically the onset of air-activated clotting. The analyzer also determines the amount of protamine necessary to neutralize the heparin in the patient's circulation.
( b ) *Classification.* Class II (special controls).
[45 FR 60601, Sept. 12, 1980, as amended at 52 FR 17733, May 11, 1987; 58 FR 51571, Oct. 4, 1993]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5260 Complement C3b inactivator immunological test system. ( a ) *Identification.* A complement C3b inactivator immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the complement C3b inactivator (a plasma protein) in serum. Complement is a group of serum proteins that destroy infectious agents. Measurement of complement C3b inactivator aids in the diagnosis of inherited antibody dysfunction.
( b ) *Classification.* Class II (performance standards).
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

                    By Notice dated October 20, 2009, and published in the                     **Federal Register**                     on October 28, 2009 (74 FR 55583), Formulation Technologies LLC., 11501 Domain Drive, Suite 130, Austin, Texas 78758, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Fentanyl (9801), a basic class of controlled substance listed in schedule II.                

The company plans to import the listed controlled substance for analytical characterization, secondary packaging, and for distribution to clinical trial sites.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Formulation Technologies LLC., to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Formulation Technologies LLC., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.

Dated: February 26, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-4722 Filed 3-4-10; 8:45 am]

BILLING CODE 4410-09-P
# C_2015294EN.01006501.xml

| 7.9.2015 | EN | Official Journal of the European Union | C 294/65 |
| --- | --- | --- | --- |

7.9.2015

EN

Official Journal of the European Union

C 294/65

---

Order of the General Court of 9 June 2015 — Fels-Werke v Commission

(Case T-281/14) (1)

1

((State aid - Measures adopted by Germany in favour of electricity generated from renewable energy sources and of energy-intensive undertakings - Decision to open the procedure under Article 108(2) TFEU - Adoption of the final decision after the action was brought - No need to adjudicate))

(2015/C 294/79)

Language of the case: German

Parties

Parties

Applicant: Fels-Werke GmbH (Goslar, Germany) (represented by: C. Arhold, N. Wimmer, F.-A. Wesche, L. Petersen and T. Woltering lawyers)

Applicant:

Defendant: European Commission (represented by: T. Maxian Rusche and R. Sauer, acting as Agents, and by C. von Donat and G. Quardt, lawyers)

Defendant:

Re:

Re:

Application to annul in part Commission decision C (2013) 4424 final of 18 December 2013 to open the procedure under Article 108(2) TFEU regarding measures implemented by the Federal Republic of Germany in favour of renewable electricity and of energy-intensive users (State aid SA.33995 (2013/C) (ex 2013/NN)).

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate on the present action. |
| --- | --- |

1.

There is no longer any need to adjudicate on the present action.

| 2. | There is no longer any need to adjudicate on the application for intervention submitted by the EFTA Surveillance Authority. |
| --- | --- |

2.

There is no longer any need to adjudicate on the application for intervention submitted by the EFTA Surveillance Authority.

| 3. | Fels-Werke GmbH shall bear its own costs and those incurred by the European Commission. |
| --- | --- |

3.

Fels-Werke GmbH shall bear its own costs and those incurred by the European Commission.

| 4. | The EFTA Surveillance Authority shall bear its own costs. |
| --- | --- |

4.

The EFTA Surveillance Authority shall bear its own costs.

---

(1)  OJ C 223, 14.7.2014.

1

---
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10329]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4668]


=======================================================================
-----------------------------------------------------------------------

SMALL BUSINESS ADMINISTRATION

[Disaster Declaration <greek-i>12053 and <greek-i>12054]


Iowa Disaster <greek-i>IA-00022

AGENCY: U.S. Small Business Administration.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a Notice of the Presidential declaration of a major 
disaster for Public Assistance Only for the State of IOWA (FEMA--1877--
DR), dated 02/25/2010.
    Incident: Severe Winter Storm and Snowstorm.
    Incident Period: 12/23/2009 through 12/27/2009.

DATES: Effective Date: 02/25/2010.
    Physical Loan Application Deadline Date: 04/26/2010.
    Economic Injury (EIDL) Loan Application Deadline Date: 11/25/2010.

ADDRESSES: Submit completed loan applications to: U.S. Small Business 
Administration, Processing and Disbursement Center, 14925 Kingsport 
Road, Fort Worth, TX 76155.

FOR FURTHER INFORMATION CONTACT: A. Escobar, Office of Disaster 
Assistance, U.S. Small Business Administration, 409 3rd Street, SW., 
Suite 6050, Washington, DC 20416.

SUPPLEMENTARY INFORMATION: Notice is hereby given that as a result of 
the President's major disaster declaration on 02/25/2010, Private Non-
Profit organizations that provide essential services of governmental 
nature may file disaster loan applications at the address listed above 
or other locally announced locations.
    The following areas have been determined to be adversely affected 
by the disaster:

Primary Counties:
    Adair, Audubon, Calhoun, Carroll, Cass, Cherokee, Clay, Crawford, 
Emmet, Franklin, Fremont, Guthrie, Harrison, Ida, Monona, Page, 
Pottawattamie, Sac, Shelby, Sioux, Woodbury.

    The Interest Rates are:

------------------------------------------------------------------------
                                                                Percent
------------------------------------------------------------------------
For Physical Damage:
    Non-Profit Organizations With Credit Available Elsewhere.      3.625
    Non-Profit Organizations Without Credit Available              3.000
     Elsewhere...............................................
For Economic Injury:
    Non-Profit Organizations Without Credit Available              3.000
     Elsewhere...............................................
------------------------------------------------------------------------

    The number assigned to this disaster for physical damage is 12053B 
and for economic injury is 12054B.

(Catalog of Federal Domestic Assistance Numbers 59002 and 59008)

James E. Rivera,
Associate Administrator, for Disaster Assistance.
[FR Doc. 2010-4668 Filed 3-4-10; 8:45 am]
BILLING CODE 8025-01-P
§ 74.1330 D&C Red No. 30. ( a ) *Identity.* ( 1 ) The color additive D&C Red No. 30 is principally 6-chloro-2-(6-chloro-4-methyl-3-oxobenzo[*b*]thien-2(3*H*)-ylidene)-4-methyl-benzo[*b*]thiophen-3(2*H*)-one (CAS Reg. No. 2379-74-0).
( 2 ) Color additive mixtures for drug use made with D&C Red No. 30 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring drugs.
( b ) *Specifications.* D&C Red No. 30 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by current good manufacturing practice: Volatile matter (at 135 °C), not more than 5 percent. Chlorides and sulfates (calculated as sodium salts), not more than 3 percent. Matter soluble in acetone, not more than 5 percent. Total color, not less than 90 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million.
( c ) *Uses and restrictions.* D&C Red No. 30 may be safely used for coloring drugs generally in amounts consistent with current good manufacturing practice.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Red No. 30 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 22510, May 25, 1982]
# C_2015354EN.01004001.xml

| 26.10.2015 | EN | Official Journal of the European Union | C 354/40 |
| --- | --- | --- | --- |

26.10.2015

EN

Official Journal of the European Union

C 354/40

---

Order of the General Court of 27 August 2015 — Squeeze Life v OHIM — Evolution Fresh (SQUEEZE LIFE)

(Case T-523/14) (1)

1

((Community trade mark - Opposition proceedings - Withdrawal of the application for registration - Correction of the decision concluding the proceedings before the Board of Appeal - No need to adjudicate))

(2015/C 354/48)

Language of the case: Spanish

Parties

Parties

Applicant: Squeeze Life, SL (Alicante, Spain) (represented by: J.-B. Devaureix and L. Montoya Terán, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: V. Melgar, Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: Evolution Fresh, Inc. (San Bernardino, California, United States)

Other party to the proceedings before the Board of Appeal of OHIM:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of OHIM of 14 April 2014 (Case R 595/2014-2) concerning opposition proceedings between Squeeze Life, SL and Evolution Fresh, Inc.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate on the action. |
| --- | --- |

1.

There is no longer any need to adjudicate on the action.

| 2. | The Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) is to bear its own costs and to pay the costs incurred by Squeeze Life, SL. |
| --- | --- |

2.

The Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) is to bear its own costs and to pay the costs incurred by Squeeze Life, SL.

---

(1)  OJ C 329, 22.9.2014.

1

---
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2360 Electrocardiograph electrode. ( a ) *Identification.* An electrocardiograph electrode is the electrical conductor which is applied to the surface of the body to transmit the electrical signal at the body surface to a processor that produces an electrocardiogram or vectorcardiogram.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9. The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Electrocardiograph Electrodes.” See § 870.1(e) for availability information of guidance documents.
[45 FR 7907, Feb. 5, 1980, as amended at 76 FR 43585, July 21, 2011]
Exhibit 23.2

Independent AUDITORS' consent

We consent to the use in this  Registration  Statement of PSEG Power LLC on Form
S-4 of our report dated March 21, 2001, appearing in the Prospectus,  which is a
part of this  Registration  Statement,  and to the  reference  to us  under  the
heading "Experts" in such Prospectus.

Deloitte & Touche LLP

Parsippany, New Jersey
September 10, 2001
<PAGE>   1
                                                                    EXHIBIT 23.2


                        CONSENT OF INDEPENDENT AUDITORS



The Board of Directors
INTERLINQ Software Corporation:


We consent to the incorporation by reference herein of our report dated July 30,
1998, with respect to the balance sheets of Interlinq Software Corporation as of
June 30, 1998 and 1997, and the related statements of operations, shareholders'
equity and cash flows for each of the years in the three-year period ended June
30, 1998, and the related schedule, which report appears in the June 30, 1998
annual report on Form 10-K of Interlinq Software Corporation and to the
reference to our firm under the heading "Experts" in the Proxy
Statement/Prospectus.



KPMG LLP

Seattle, Washington
January 22, 1999
# C_2014261EN.01001501.xml

| 11.8.2014 | EN | Official Journal of the European Union | C 261/15 |
| --- | --- | --- | --- |

11.8.2014

EN

Official Journal of the European Union

C 261/15

---

Request for a preliminary ruling from the Korkein hallinto-oikeus (Finland) lodged on 30 May 2014 — Kansaneläkelaitos, Suomen Palvelutaksit ry, Oulun Taksipalvelut Oy

(Case C-269/14)

2014/C 261/22

Language of the case: Finnish

Referring court

Referring court

Korkein hallinto-oikeus

Parties to the main proceedings

Parties to the main proceedings

Appellants: Kansaneläkelaitos, Suomen Palvelutaksit ry, Oulun Taksipalvelut Oy

Appellants:

Other parties: Suomen Taksiliitto ry, Turun Seudun Invataksit ry, Hämeen Taksi Oy, Itä-Suomen Maakunnallinen Taksi Oy, Kainuun Taksivälitys Oy, Keski-Suomen Taksi Oy, Lounais-Suomen Taxidata Oy, Pohjois-Suomen Taksi Oy

Other parties:

Questions referred

Questions referred

| 1) | Must the case-law of the Court of Justice concerning a service concession be understood as meaning that it does not extend to a complex arrangement which includes the payment of reimbursements within the authority’s organisational responsibility in the form of a direct reimbursement scheme and at the same time a system of booking journeys which is not within the authority’s responsibility? |
| --- | --- |

1)

Must the case-law of the Court of Justice concerning a service concession be understood as meaning that it does not extend to a complex arrangement which includes the payment of reimbursements within the authority’s organisational responsibility in the form of a direct reimbursement scheme and at the same time a system of booking journeys which is not within the authority’s responsibility?

| 2) | What significance should be attached to the indirect consequence of the scheme that the purpose of the booking system is to reduce the transport costs payable from public funds by the Kansaneläkelaitos? |
| --- | --- |

2)

What significance should be attached to the indirect consequence of the scheme that the purpose of the booking system is to reduce the transport costs payable from public funds by the Kansaneläkelaitos?

---
§ 529.536 Detomidine. ( a ) *Specifications.* Each milliliter of gel contains 7.6 milligrams (mg) of detomidine hydrochloride.
( b ) *Sponsor.* See No. 052483 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 0.018 mg per pound (mg/lb) (0.040 mg/kilogram (kg) sublingually.
( 2 ) *Indications for use.* For sedation and restraint.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.
[75 FR 21163, Apr. 23, 2010, as amended at 76 FR 16533, Mar. 24, 2011]
Exhibit 32.2

CERTIFICATION PURSUANT TO  SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant
to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Chief Financial Officer of
The Timberland Company (the "Company"), does hereby certify that to the undersigned's knowledge:



| |  |  | /s/BRIAN P. MCKEONBrian P. McKeon
Chief Financial Officer
| |  |  | ---------------------------------------------------------

Date:
May 12, 2004

The
foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of
Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A
signed original of this written statement, required by Section 906, has been provided to The Timberland Company and will be retained by The Timberland Company and furnished to the Securities
and Exchange Commission or its staff upon request.

---



QuickLinks
(logo)WELLS FARGO**           Commercial Mortgage Servicing**

   D1050-084, 8th Floor 

   401 South Tryon Street 

   Charlotte, NC 28202

   1-800-326-1334

 

 

**ANNUALSTATEMENT OF COMPLIANCE**

** **

Reference is hereby made to that certainPooling and Servicing Agreement dated as of June 1, 2015, by and among MorganStanley Capital I Inc., as Depositor, Wells Fargo Bank, National Association,as Master Servicer, LNR Partners, LLC, as General Special Servicer, Wells FargoBank, National Association, as Excluded Mortgage Loan Special Servicer,Pentalpha Surveillance LLC, as Trust Advisor, Wilmington Trust, NationalAssociation, as Trustee, and Wells Fargo Bank, National Association, asCertificate Administrator, Certificate Registrar, Authenticating Agent andCustodian with respect to Commercial Mortgage Pass-Through Certificates Series2015-C23 (the "Agreement"). Capitalized terms used herein nototherwise defined shall have the meanings assigned in theAgreement.

 

Pursuant to Section 13.9 of the Agreement,I, Daniel Bober, Executive Vice President of Commercial Mortgage Services dohereby certify that:

 

1. A review of the activities of theMaster Servicer during the period from January 1, 2017 through December 31,2017 (the “Reporting Period”), and of its performance per the Agreement duringsuch period has been made under my supervision,and

 

2.To the best of my knowledge, based on such review, the Master Servicer, hasfulfilled all of its obligations under the Agreement in all material respectsthroughout the ReportingPeriod.

 

 

IN WITNESS WHEREOF, the undersigned hasexecuted this Certificate as of the 28th day of February2018.

 

/s/Daniel Bober  

Daniel Bober

Executive Vice President 

Wells Fargo Bank

 

 

WellsFargo Bank, N.A.                                                                         (logo)Together we’ll go far
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.4540 Immunonephelometer equipment. ( a ) *Identification.* Immunonephelometer equipment for clinical use with its electrical power supply is a device that measures light scattering from antigen-antibody complexes. The concentration of these complexes may be measured by means of reflected light. A beam of light passed through a solution is scattered by the particles in suspension. The amount of light is detected by a photodetector, which converts light energy into electrical energy. The amount of electrical energy registers on a readout system such as a digital voltmeter or a recording chart. This electrical readout is called the light-scattering value and is used to measure the concentration of antigen-antibody complexes. This generic type of device includes devices with various kinds of light sources, such as laser equipment.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25047, June 12, 1989; 66 FR 38792, July 25, 2001]